55440

Savings and quaternary prevention

ANA RITA DA SILVA MATOS DE JESUS FAUSTINO 1 ; MARTA ALVES RIBEIRO 2 ; NATALIA MARIA LOURENÇO SIMÕES 1
Favorite this paper

introduction: In 2012 ,the European Medicines Agency (EMA) and the Committee for Medicinal Products for Human use (CHMP) concluded that trimetazidine has not demonstrated benefit intreating tinnitus,vertigo or visual disturbances,keeping only the indication in the prophylaxis of angina pectoris.It was recommended by Infarmed to withdrawing its prescription in patients for whom there is no indication. Method: research through statistical program Mim@uf Objectives: The Work consists in the verification of compliance with the recommendation of the EMA between 2012 and 2015 in the universe of the elderly Family Health Unit D.Diniz ( n= 2163) and reducing associated costs. Conclusions: It was observed the gradual decrease of the prescription as standard of EMA and Infarmed : 6.75% of the elderly used trimetazidine in 2012 and only 1.1% took it in 2015. Besides quaternary prevention, reduction of costs was about 23 248 Euros.